M&A Deal Summary

Vaxart Acquires Aviragen Therapeutics

On October 30, 2017, Vaxart acquired life science company Aviragen Therapeutics

Acquisition Highlights
  • This is Vaxart’s 1st transaction in the Life Science sector.
  • This is Vaxart’s 1st transaction in the United States.
  • This is Vaxart’s 1st transaction in Georgia.

M&A Deal Summary
Date 2017-10-30
Target Aviragen Therapeutics
Sector Life Science
Buyer(s) Vaxart
Deal Type Merger
Advisor(s) Stifel, Nicolaus & Co., Inc. (Financial)
Dechert (Legal)

Target

Aviragen Therapeutics

Alpharetta, Georgia, United States
Aviragen Therapeutics, Inc. is a developer of innovative products for the prevention and treatment of serious and potentially life-threatening infectious diseases.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Vaxart

South San Francisco, California, United States
Category Company
Sector Life Science
Employees28
Revenue 7M USD (2023)
DESCRIPTION

Vaxart is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart is based in South San Francisco, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Merger) 1 of 1
State (Georgia) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
Mergr

Product

Company

Legal